SEQUENCE LISTING

<110> Eli Lilly and Company

<120> METHODS OF USING A GIP/GLP1 CO-AGONIST FOR THERAPY

<130> X22001

<150> US 62/702,061
<151> 2018-07-23

<150> US 62/730,565
<151> 2018-08-13

<150> US 62/740,619
<151> 2018-10-03

<160> 1

<170> PatentIn version 3.5

<210> 1
<211> 39
<212> PRT
<213> Artificial Sequence

<220>
<223> Synthetic Construct

<220>
<221> MISC_FEATURE
<222> (2)..(2)
<223> Xaa at position 2 is nonnaturally occurring amino acid
2-Aminoisobutyric Acid

<220>
<221> MISC_FEATURE
<222> (13)..(13)
<223> Xaa at position 13 is nonnaturally occurring amino acid
2-Aminoisobutyric Acid

<220>
<221> MOD_RES
<222> (20)..(20)
<223> Lys at position 20 is chemically modified through conjugation to
the epsilon-amino group of the K side-chain with
(2-[2-(2-Amino-ethoxy)-ethoxy]-acetyl)2-(gamma-Glu)1-CO-(CH2)18-C
O2H

<220>
<221> MOD_RES
<222> (39)..(39)
<223> Ser at position 39 is amidated as a C-terminal primary amide

<400> 1

Tyr Xaa Glu Gly Thr Phe Thr Ser Asp Tyr Ser Ile Xaa Leu Asp Lys
1 5 10 15

Ile Ala Gln Lys Ala Phe Val Gln Trp Leu Ile Ala Gly Gly Pro Ser
20 25 30

Ser Gly Ala Pro Pro Pro Ser
35